Patent Theme
Targeted Protein Degradation
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
18,167 US filings from 5,322 companies since 2023 · 2023: 4,479 · 2024: 5,922 · 2025: 5,505 · 2026 YTD: 2,261
Heterocyclic Compounds (Pharma)
Top companies
Ranked by filings in this theme since 2023. 2026 is partial.
| # | Company | Since 2023 | 2023 | 2024 | 2025 | 2026 YTD | YoY |
|---|
| 1 | The Regents of the University of California | 284 | 82 | 102 | 69 | 31 | -32.4% |
| 2 | Dana-Farber Cancer Institute, Inc. | 207 | 53 | 61 | 63 | 30 | +3.3% |
| 3 | Hoffmann-La Roche Inc. | 157 | 41 | 44 | 47 | 25 | +6.8% |
| 4 | Novartis AG | 143 | 35 | 48 | 37 | 23 | -22.9% |
| 5 | Genentech, Inc. | 140 | 43 | 37 | 46 | 14 | +24.3% |
| 6 | Regeneron Pharmaceuticals, Inc. | 132 | 28 | 40 | 50 | 14 | +25.0% |
| 7 | UNIVERSITY OF MASSACHUSETTS | 132 | 29 | 36 | 44 | 23 | +22.2% |
| 8 | Incyte Corporation | 128 | 21 | 49 | 39 | 19 | -20.4% |
| 9 | Ionis Pharmaceuticals, Inc. | 128 | 33 | 41 | 40 | 14 | -2.4% |
| 10 | Dyne Therapeutics, Inc. | 114 | 29 | 41 | 40 | 4 | -2.4% |
| 11 | Kymera Therapeutics, Inc. | 112 | 37 | 23 | 32 | 20 | +39.1% |
| 12 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 112 | 35 | 40 | 23 | 14 | -42.5% |
| 13 | The Board of Trustees of the Leland Stanford Junior University | 110 | 30 | 40 | 29 | 11 | -27.5% |
| 14 | President and Fellows of Harvard College | 107 | 31 | 35 | 23 | 18 | -34.3% |
| 15 | Merck Sharp & Dohme LLC | 105 | 27 | 39 | 24 | 15 | -38.5% |
| 16 | Yale University | 102 | 26 | 38 | 32 | 6 | -15.8% |
| 17 | The Broad Institute, Inc. | 99 | 20 | 29 | 39 | 11 | +34.5% |
| 18 | ARVINAS OPERATIONS, INC. | 98 | 13 | 38 | 31 | 16 | -18.4% |
| 19 | Revolution Medicines, Inc. | 98 | 20 | 25 | 40 | 13 | +60.0% |
| 20 | AMGEN INC. | 92 | 12 | 23 | 40 | 17 | +73.9% |
| 21 | The Johns Hopkins University | 92 | 25 | 29 | 26 | 12 | -10.3% |
| 22 | Wyvern Pharmaceuticals Inc. | 92 | · | 3 | 59 | 30 | +1866.7% |
| 23 | Board of Regents, The University of Texas System | 90 | 31 | 25 | 27 | 7 | +8.0% |
| 24 | The General Hospital Corporation | 85 | 28 | 27 | 20 | 10 | -25.9% |
| 25 | Bristol-Myers Squibb Company | 80 | 20 | 29 | 25 | 6 | -13.8% |